budesonide
Article
budesonide is a recurring brand in the Astral Codex Ten archive, appearing 2 times across 2 issues between December 22, 2021 and December 22, 2021. The archive places it in contexts such as “fluvoxamine and budesonide are both appropriate to prescribe”. It most often appears alongside FDA, fluvoxamine, Luvox.
Metadata
- Category: Brands
- Mention count: 2
- Issue count: 2
- First seen: December 22, 2021
- Last seen: December 22, 2021
Appears In
- The FDA Has Punted Decisions About Luvox Prescription To The Deepest Recesses Of The Human Soul
- Addendum To Luvox Post
Related Pages
-
- FDA (2 shared issues)
-
- fluvoxamine (2 shared issues)
-
- Luvox (2 shared issues)
-
- Merck (2 shared issues)
-
- molnupiravir (2 shared issues)
-
- Vox (2 shared issues)
-
- aspirin (1 shared issues)
-
- Astralcodexten Com (1 shared issues)
-
- Congo (1 shared issues)
-
- COVID (1 shared issues)
-
- CS Lewis (1 shared issues)
-
- Dr. Ed Mills (1 shared issues)
External Links
Source Context
Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.
[Professor Ed] Mills, who thinks that fluvoxamine and budesonide are both appropriate to prescribe to patients sick with Covid-19, compares public messaging on fluvoxamine to communications about Merck’s drug molnupiravir. The evidence for molnupiravir is in many ways weaker than the evidence for fluvoxamine, but molnupiravir was produced by a major pharmaceutical company that can shepherd it through the process of becoming a recommended drug. On a call last week, Mills said, the FDA told him “they don’t know how to deal with submissions where there isn’t someone to be responsible for it.”
[Professor Ed] Mills, who thinks that fluvoxamine and budesonide are both appropriate to prescribe to patients sick with Covid-19, compares public messaging on fluvoxamine to communications about Merck’s drug molnupiravir. The evidence for molnupiravir is in many ways weaker than the evidence for fluvoxamine, but molnupiravir was produced by a major pharmaceutical company that can shepherd it through the process of becoming a recommended drug. On a call last week, Mills said, the FDA told him “they don’t know how to deal with submissions where there isn’t someone to be responsible for it.”